Thursday 21 November 2024

The Pharma Letter Podcast — Episode 11 — Should US states control drug prices?

Biotechnology
Simon Wentworth
4 March 2022
episode11-big

More on this story...

Pharmaceutical
The Pharma Letter Podcast — Episode 10 — Will decentralized clinical trials become the new standard?
10 February 2022
Biotechnology
The Pharma Letter Podcast — Episode 9 — The rise of AI in drug discovery
30 December 2021
Biotechnology
The Pharma Letter Podcast — Episode 8 — Why hasn't the world embraced Sputnik V?
14 December 2021
Pharmaceutical
Will the unintended consequences of drug price transparency regulation outweigh its benefits?
18 March 2022


More ones to watch >


Today's issue

EC approval for Pfizer’s Hympavzi
Biotechnology
EC approval for Pfizer’s Hympavzi
20 November 2024
Biotechnology
Flagship reveals new agreements under Pfizer link-up
20 November 2024
Pharmaceutical
Ascentage's lisaftoclax accepted for priority review in China
20 November 2024
Biosimilars
Xbrane and Intas to jointly develop Opdivo biosimilar
20 November 2024
Pharmaceutical
Chris Boshoff takes on new role at Pfizer
20 November 2024
Biotechnology
Two Neds better than one in Jupiter’s world of moons
20 November 2024
Pharmaceutical
Cytokinetics and Bayer ink deal for aficamten in Japan
20 November 2024

Company Spotlight

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.




More Features in Biotechnology

EC approval for Pfizer’s Hympavzi
20 November 2024
Flagship reveals new agreements under Pfizer link-up
20 November 2024
Two Neds better than one in Jupiter’s world of moons
20 November 2024
JAK inhibitors redefining atopic dermatitis treatment
20 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze